MicroRNA signature in patients with hepatocellular carcinoma associated with type 2 diabetes

Table 2 Clinical and laboratory aspects of the first confirmation analysis recruited patients

Parameter	LC, n = 50	HCC, n = 50	P value
Age in yr	55.63 ± 7.69	58.65 ± 8.97	NS
Male sex	66%	66%	NS
ALT in IU/L	76.98 ± 65.83	78.53 ± 43.19	NS
AST in IU/L	69.17 ± 63.36	62.78 ± 43.32	NS
Total bilirubin in mg/dL	2.53 ± 1.94	2.79 ± 1.78	NS
Albumin in g/dL	2.59 ± 1.47	2.45 ± 1.62	NS
ALP in IU/L	134.6 ± 83.5	103.18 ± 37.5	NS
Creatinine in mg/dL	0.98 ± 0.3	1.38 ± 0.87	NS
Hemoglobin in g/dL	11.42 ± 1.23	11.35 ± 1.68	NS
AFP in ng/mL	27.56 ± 41.23	165.49 ± 214.56	< 0.005
Platelet count as × 103/µL	96.7 ± 51.6	149.7 ± 129.3	< 0.005
Leukocyte count as × 103/µL	6.98 ± 2.98	7.61 ± 4.3	< 0.005
BCLC stage, n (%)
A		20 (40)
B		26 (52)
C		4 (8)

Data are presented as mean ± standard deviation. Clinical data was analyzed by analysis of variance analysis. Results were considered to be statistically significant if P < 0.05. AFP: Alpha-fetoprotein; ALP: Alkaline phosphatase; ALT: Alanine amino transferase; AST: Aspartate amino transferase; BCLC: Barcelona clinic liver cancer; HCC: Hepatocellular carcinoma; LC: Liver cirrhosis.